Prognostic significance of PD-L1 in patients with non-small cell lung cancer: A large cohort study of surgically resected cases

Journal of Thoracic Oncology

Volumn 11, Issue 7, 2016, Pages 1003-1011

  Sun, Jong Mu ^a   Zhou, Wei ^b   Choi, Yoon La ^a   Choi, So Jung ^a   Kim, Se Eun ^a   Wang, Zhen ^b   Dolled Filhart, Marisa ^b   Emancipator, Kenneth ^b   Wu, Dianna ^b   Weiner, Russell ^b   Frisman, D ^c   Kim, Hong Kwan ^a   Choi, Yong Soo ^a   Shim, Young Mog ^a   Kim, Jhingook ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b MERCK RESEARCH LABORATORIES   (United States)

^c QualTek Molecular Laboratories   (United States)

Author keywords

Immunomodulation; Laboratory correlates; Molecular diagnosis and prognosis; PD L1

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ADULT; AGE; AGED; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS;

ADULT; AGED; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 84978225996     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.04.007     Document Type: Conference Paper

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
3. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
4. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-144.
5. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer [abstract]. J Clin Oncol. 2014;32(suppl 5):6011.
6. Kefford R, Ribas A, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstract]. J Clin Oncol. 2014;32(suppl 5):3005.
7. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387: 1540-1550.
8. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [e-pub ahead of print]. Lancet. doi: 10.1016/S0140-6736(16)00587-0, accessed May 7, 2016.
9. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Eng J Med. 2015;372:2018-2028.
10. Choueiri TK, Fishman MN, Escudier BJ, et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial [abstract]. J Clin Oncol. 2014;32(suppl 5):5012.
11. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012;98:751-755.
12. Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Oncotargets Ther. 2014;7:567-573.
13. Yang CY, Lin MW, Chang YL, et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014;50:1361-1369.
14. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107-116.
15. Marti AM, Martinez P, Navarro A, et al. Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung [abstract]. J Clin Oncol. 2014;32(suppl 5):7569.
16. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10: 5094-5100.
17. Boland JM, Kwon ED, Harrington SM, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer. 2013;14:157-163.
18. Wang A, Wang HY, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015;41: 450-456.
19. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2: 706-714.
20. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
21. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. J Clin Oncol. 2008;26:5043-5051.
22. Xu C, Fillmore CM, Koyama S, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PDL1 expression. Cancer Cell. 2014;25:590-604.
23. Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer. 2013;49:2233-2242.
24. Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20:2773-2782.
25. Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1:54-63.